MIPROXIFENE PHOSPHATE

Details

Stereochemistry	ACHIRAL
Molecular Formula	C29H36NO5P
Molecular Weight	509.5736
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	1
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CC\C(=C(\C1=CC=C(OCCN(C)C)C=C1)C2=CC=C(OP(O)(O)=O)C=C2)C3=CC=C(C=C3)C(C)C

InChI

InChIKey=QZUHFMXJZOUZFI-ZQHSETAFSA-N

InChI=1S/C29H36NO5P/c1-6-28(23-9-7-22(8-10-23)21(2)3)29(25-13-17-27(18-14-25)35-36(31,32)33)24-11-15-26(16-12-24)34-20-19-30(4)5/h7-18,21H,6,19-20H2,1-5H3,(H2,31,32,33)/b29-28+

HIDE SMILES / InChI

Molecular Formula	C29H36NO5P
Molecular Weight	509.5736
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	1
Optical Activity	NONE

Description
Sources: http://www.europeanmedical.info/prodrugs/tat59-miproxifene-phosphate.html
Curator's Comment: Description was created based on several sources, including http://www.ncbi.nlm.nih.gov/pubmed/1893497

TAT-59 (Miproxifene Phosphate) is a triphenylethylene analog of tamoxifen. TAT-59 is the phosphate ester prodrug of the practically insoluble parent drug DP-TAT-59. It is an antiestrogen developed in Japan for breast cancer. It is a potent antitumor agent for hormone-dependent tumors. Most of TAT-59 metabolites possessed remarkable binding affinity toward estrogenic receptors as well as fairly good antiuterotrophic activity.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Estrogen receptor 75 Target ID: CHEMBL2093866 Sources: https://www.ncbi.nlm.nih.gov/pubmed/2141500	Antagonist 2778

Conditions

Condition	Modality	Targets	Highest Phase	Product
Breast cancer 434 Sources: http://www.ncbi.nlm.nih.gov/pubmed/9530362	Primary		Withdrawn	Unknown Approved Use Unknown

PubMed

Title	Date	PubMed
[Steady state and disappearance of the metabolites of miproxifene phosphate in the treatment of breast cancer].	1998 Aug	9725050
[Late phase II study of TAT-59 (miproxifene phospate) in advanced or recurrent breast cancer patients (a double-blind comparative study with tamoxifen citrate)].	1998 Jun	9644320
Estrogen agonistic/antagonistic effects of miproxifene phosphate (TAT-59).	2000	10663628

Patents

Sample Use Guides

In Vivo Use Guide

20 mg/day

Route of Administration: Oral

In Vitro Use Guide

TAT-59 given at 1, 5, and 20 mg/kg inhibited the estrogen-stimulated growth of MCF-7 tumors in athymic mice in a dose-dependent fashion.

Substance Class	Chemical Created by `admin` on `Fri Dec 15 19:42:10 GMT 2023` Edited by `admin` on `Fri Dec 15 19:42:10 GMT 2023`
Record UNII	QAK0B78ZCL
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

MIPROXIFENE PHOSPHATE

Common Name

English

PHENOL, 4-((1E)-1-(4-(2-(DIMETHYLAMINO)ETHOXY)PHENYL)-2-(4-(1-METHYLETHYL)PHENYL)-1-BUTEN-1-YL)-, 1-(DIHYDROGEN PHOSPHATE)

Common Name

English

TAT-59

Code

English

PHENOL, 4-(1-(4-(2-(DIMETHYLAMINO)ETHOXY)PHENYL)-2-(4-(1-METHYLETHYL)PHENYL)-1-BUTENYL)-, DIHYDROGEN PHOSPHATE (ESTER), (E)-

Common Name

English

MIPROXIFENE PHOSPHATE [JAN]

Common Name

English

PHENOL, 4-((1E)-1-(4-(2-(DIMETHYLAMINO)ETHOXY)PHENYL)-2-(4-(1-METHYLETHYL)PHENYL)-1-BUTENYL)-, DIHYDROGEN PHOSPHATE (ESTER)

Common Name

English

TAT 59

Code

English

Code System Code Type Description

WIKIPEDIA

Miproxifene phosphate